$ABT

3 theses

bullish 67%neutral 0%bearish 33%

Avg return (1m)

+1.2%

Win rate (1m)

100% (3 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:30 PM ET

$ABTSEC Form 4bearish

Morrone Louis H. · EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES · 48d agono track record yet

Sold 5,850 @ $109.83 avg · $642,506 · 2026-08-11

Form 4: Morrone Louis H. sold ABT

Morrone Louis H. (EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES) reported an open-market sale of 5,850 shares of ABT at an average $109.83, roughly $642,506, in a Form 4 filed 2026-08-13.

At post $111.27Now $102.61-7.8% since postedas of Sep 18, 4:30 PM ET

1d-0.0%

3d-0.0%

1w+2.6%

1m-8.4%

3m—

6m—

1y—

View filing on SEC.gov →

$ABTr/ValueInvestingDiscussionbullish

u/Idntevncare · 55d ago8 prior · awaiting results

HEALTHCARE is a great value right now

Abbott Laboratories is positioned as a value play in the healthcare sector, with structural growth from aging demographics and potential AI applications in life-saving products.

At post $107.96Now $102.61-5.0% since postedas of Sep 18, 4:30 PM ET

1d-0.1%

3d-0.1%

1w+3.1%

1m+0.3%

3m—

6m—

1y—

original post →

$ABTr/ValueInvestingIndustry/Sectorbullish

u/raytoei · 68d ago17 prior · awaiting results

Medical-Device Stocks Are in the Bargain Bin. 6 to Buy - Barron’s

Abbott has posted stronger margins and is launching new devices for arrhythmias and diabetes monitoring, with analyst price targets implying 15% upside. Medical-device valuations at 20-30% discounts to the S&P 500 with 5-6% free-cash-flow yields offer compelling entry points as sector fears prove overblown.

At post $104.49Now $102.61-1.8% since postedas of Sep 18, 4:30 PM ET

1d—

3d+2.7%

1w+1.2%

1m+11.7%

3m—

6m—

1y—

original post →

End of results.